We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Impact of PARP inhibitor on QOL including nausea and vomiting per diem in ovarian cancer patients: prospective observational study.
- Authors
Myong cheol Lim; Young wook Jeong; Ji hyun Kim; Yoon jung Chang; Sang-yoon Park
- Abstract
Objective: Poly (ADP-ribose) polymerase (PARP) inhibitors are used for ovarian cancer patients responding with postoperative adjuvant chemotherapy, based on the BRCA/homologous recombination deficiency status. Toxicity profiles are quite different according to the type of PARP inhibitors. Especially, pattern of nausea and vomiting per diem is quite different basically according to number of doses administered of different type of PARP inhibitor. This study aimed to investigate the patterns of nausea and vomiting per diem, and overall quality of life in ovarian cancer patients with the use of PARP inhibitors. Methods: We have enrolled stage III-IV ovarian cancer patients who initiate maintenance treatment with niraparib or olaparib since December 14, 2023. Four-week diary for recording the pattern of nausea and vomiting per diem, and other behavioral patterns which could affect nausea and vomiting, including eating habit, antiemetic use, physical activity and sleeping patterns. During 4-week diary, consecutive EORTC QLQ OV-28 and EQ-5D-3L questionnaires are also assessed. Results: The results will be collected and analyzed before early April 2023. Conclusion: This will be presented on the congress.
- Subjects
OVARIAN cancer; POLY(ADP-ribose) polymerase; CANCER patients; HOMOLOGOUS recombination; NAUSEA; POLYMERASES
- Publication
Journal of Gynecologic Oncology, 2024, Vol 35, p43
- ISSN
2005-0380
- Publication type
Article
- DOI
10.3802/jgo.2024.35.S2.P44